

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Nivolumab for relapsed or refractory classical Hodgkin lymphoma**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was noted that if the remit ends up only including relapsed or refractory classical Hodgkin lymphoma following autologous stem cell transplant and brentuximab vedotin, this will discriminate against older people, and those with co-morbidities in whom autologous stem cell transplant is not an option.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The remit is currently broad, including 'relapsed or refractory classical Hodgkin lymphoma'. This covers both groups of people referred to above. If the final marketing authorisation is restricted to 1 group, NICE can only appraise nivolumab for that group, in line with the marketing authorisation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
No.

**Approved by Associate Director (name):** ...Frances Sutcliffe.....

**Date:** 02/09/2016